Transatlantic Comparison of Pediatric Continuous Glucose Monitoring Use in the Diabetes-Patienten-Verlaufsdokumentation Initiative and Type 1 Diabetes Exchange Quality Improvement Collaborative

Abstract
Achieving glycemic targets in youth and young adults with type 1 diabetes (T1D) is challenging. Diabetes
devices, including continuous glucose monitors (CGM) may impact glycemic control. We analyzed the proportion
of CGM use in youth and young adults with T1D at nine U.S. T1D Exchange Quality Improvement
(T1DX-QI) Collaborative centers and 402 European diabetes prospective follow-up registry (Diabetes-
Patienten-Verlaufsdokumentation [DPV]) sites from 2017 to 2020 and examined the association of CGM use to
glycemic control as measured by hemoglobin A1c (HbA1c). CGM use increased each year from 2017 to 2020
across all age ranges (<6, 6–<12, 12–<18, 18–<25 years) in both registries and lower mean HbA1c was
observed in CGM users compared with nonusers regardless of insulin delivery method for all years analyzed.
CGM use appeared to increase more so in the European DPV than the U.S. T1DX-QI, which may be due to
transatlantic differences in health care systems, insurance coverage, and prescriber habits.

dia.2022.0248